Literature DB >> 33770254

CCL5 production by fibroblasts through a local renin-angiotensin system in malignant melanoma affects tumor immune responses.

Kenta Nakamura1, Yukiko Kiniwa2, Ryuhei Okuyama2.   

Abstract

PURPOSE: To enhance the antitumor effects of anti-programmed death-1 (PD-1) antibodies, it is important to reverse cancer-induced immunosuppression. We previously reported that a localized renin-angiotensin system in the tumor microenvironment inhibited tumor immunity via macrophages. In this study, we analyzed the underlying mechanism through which fibroblasts express tumor immunity influenced by the angiotensin receptor.
METHODS: We used an angiotensin receptor inhibitor (ARB) to inhibit renin-angiotensin system. Furthermore, angiotensin receptors were knocked out from mice fibroblasts, which were then collected. The fibroblasts and a malignant melanoma were then transfused into a mouse model and tumor immunity response was analyzed.
RESULTS: Fibroblasts produced CC motif chemokine ligand 5 (CCL5) on renin-angiotensin system stimulation, and this production decreased after ARB administration. In mice with transplanted malignant melanoma, ARB administration resulted in decreased CCL5 concentration in the blood, increase in tumor-infiltrating T cells, decrease in regulatory T cells, as well as an increase in tumor antigen-specific T-cell responses. The mice in which the angiotensin receptor knockout fibroblasts and malignant melanoma were transplanted showed a similar decrease in CCL5 concentration and increased tumor antigen-specific T-cell responses. Furthermore, ARB and anti-PD-1 antibody were administered in combination, which resulted in significantly better tumor growth inhibition over monotherapy.
CONCLUSION: Inhibiting renin-angiotensin system restored the therapeutic efficacy of inhibited anti-PD-1 antibodies. Thus, this could be considered a valid approach to enhance the therapeutic efficacy of anti-PD-1 antibodies.

Entities:  

Keywords:  CCL5; Cancer-associated fibroblast; Programmed death-1; Renin–angiotensin system

Year:  2021        PMID: 33770254     DOI: 10.1007/s00432-021-03612-8

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  35 in total

1.  Tumor-derived chemokine CCL5 enhances TGF-β-mediated killing of CD8(+) T cells in colon cancer by T-regulatory cells.

Authors:  Li-Yuan Chang; Yung-Chang Lin; Jayashri Mahalingam; Ching-Tai Huang; Ten-Wen Chen; Chiao-Wen Kang; Hui-Min Peng; Yu-Yi Chu; Jy-Ming Chiang; Avijit Dutta; Yuan-Ji Day; Tse-Ching Chen; Chau-Ting Yeh; Chun-Yen Lin
Journal:  Cancer Res       Date:  2012-01-26       Impact factor: 12.701

2.  Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors.

Authors:  Benjamin Diop-Frimpong; Vikash P Chauhan; Stephen Krane; Yves Boucher; Rakesh K Jain
Journal:  Proc Natl Acad Sci U S A       Date:  2011-01-31       Impact factor: 11.205

3.  Angiotensin II modulates VEGF-driven angiogenesis by opposing effects of type 1 and type 2 receptor stimulation in the microvascular endothelium.

Authors:  Javier Carbajo-Lozoya; Susanne Lutz; Yuxi Feng; Jens Kroll; Hans-Peter Hammes; Thomas Wieland
Journal:  Cell Signal       Date:  2012-02-20       Impact factor: 4.315

4.  [Disturbances of the intestinal circulation].

Authors: 
Journal:  Ugeskr Laeger       Date:  1969-04-17

5.  Reprogramming the microenvironment with tumor-selective angiotensin blockers enhances cancer immunotherapy.

Authors:  Vikash P Chauhan; Ivy X Chen; Rong Tong; Mei Rosa Ng; John D Martin; Kamila Naxerova; Michelle W Wu; Peigen Huang; Yves Boucher; Daniel S Kohane; Robert Langer; Rakesh K Jain
Journal:  Proc Natl Acad Sci U S A       Date:  2019-04-30       Impact factor: 11.205

6.  Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial.

Authors:  Charles S Fuchs; Toshihiko Doi; Raymond W Jang; Kei Muro; Taroh Satoh; Manuela Machado; Weijing Sun; Shadia I Jalal; Manish A Shah; Jean-Phillipe Metges; Marcelo Garrido; Talia Golan; Mario Mandala; Zev A Wainberg; Daniel V Catenacci; Atsushi Ohtsu; Kohei Shitara; Ravit Geva; Jonathan Bleeker; Andrew H Ko; Geoffrey Ku; Philip Philip; Peter C Enzinger; Yung-Jue Bang; Diane Levitan; Jiangdian Wang; Minori Rosales; Rita P Dalal; Harry H Yoon
Journal:  JAMA Oncol       Date:  2018-05-10       Impact factor: 31.777

7.  Role of host angiotensin II type 1 receptor in tumor angiogenesis and growth.

Authors:  Kimiyasu Egami; Toyoaki Murohara; Toshifumi Shimada; Ken-Ichiro Sasaki; Satoshi Shintani; Takeshi Sugaya; Masahiro Ishii; Teiji Akagi; Hisao Ikeda; Toyojiro Matsuishi; Tsutomu Imaizumi
Journal:  J Clin Invest       Date:  2003-07       Impact factor: 14.808

8.  Cancer-associated fibroblasts and M2-polarized macrophages synergize during prostate carcinoma progression.

Authors:  G Comito; E Giannoni; C P Segura; P Barcellos-de-Souza; M R Raspollini; G Baroni; M Lanciotti; S Serni; P Chiarugi
Journal:  Oncogene       Date:  2013-06-03       Impact factor: 9.867

9.  Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.

Authors:  Robert L Ferris; George Blumenschein; Jerome Fayette; Joel Guigay; A Dimitrios Colevas; Lisa Licitra; Kevin Harrington; Stefan Kasper; Everett E Vokes; Caroline Even; Francis Worden; Nabil F Saba; Lara C Iglesias Docampo; Robert Haddad; Tamara Rordorf; Naomi Kiyota; Makoto Tahara; Manish Monga; Mark Lynch; William J Geese; Justin Kopit; James W Shaw; Maura L Gillison
Journal:  N Engl J Med       Date:  2016-10-08       Impact factor: 91.245

10.  Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer.

Authors:  Christine Feig; James O Jones; Matthew Kraman; Richard J B Wells; Andrew Deonarine; Derek S Chan; Claire M Connell; Edward W Roberts; Qi Zhao; Otavia L Caballero; Sarah A Teichmann; Tobias Janowitz; Duncan I Jodrell; David A Tuveson; Douglas T Fearon
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-25       Impact factor: 11.205

View more
  2 in total

Review 1.  Insights Into Vascular Anomalies, Cancer, and Fibroproliferative Conditions: The Role of Stem Cells and the Renin-Angiotensin System.

Authors:  Ethan J Kilmister; Swee T Tan
Journal:  Front Surg       Date:  2022-04-27

2.  Tumor bud-derived CCL5 recruits fibroblasts and promotes colorectal cancer progression via CCR5-SLC25A24 signaling.

Authors:  Ling-Fang Gao; Yan Zhong; Ting Long; Xia Wang; Jia-Xian Zhu; Xiao-Yan Wang; Zhi-Yan Hu; Zu-Guo Li
Journal:  J Exp Clin Cancer Res       Date:  2022-03-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.